Keynote 224 Results Kite

Keynote 224 Results Kite. In the keynote study, a conventional dose of pembrolizumab, 200 mg iv every 3 weeks, was used in a cohort of patients who had failed or progressed on. We aimed to assess the efficacy and safety of.

In the keynote study, a conventional dose of pembrolizumab, 200 mg iv every 3 weeks, was used in a cohort of patients who had failed or progressed on. The study presented on pembrolizumab is very interesting.